AbbVie Inc (ABBV)vsFortress Biotech Inc (FBIO)
ABBV
AbbVie Inc
$264.34
-0.29%
HEALTHCARE · Cap: $454.36B
FBIO
Fortress Biotech Inc
$2.28
0.00%
HEALTHCARE · Cap: $84.04M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 93941% more annual revenue ($64.39B vs $68.47M). FBIO leads profitability with a 163.3% profit margin vs 9.8%. FBIO trades at a lower P/E of 0.9x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
FBIO
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.34
$112.18 premium
Margin of Safety
+73.4%
Fair Value
$13.79
Current Price
$2.28
$11.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 163 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -108.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : FBIO
The strongest argument for FBIO centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : FBIO
The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while FBIO is a mature play — different risk/reward profiles.
FBIO carries more volatility with a beta of 1.19 — expect wider price swings.
FBIO is growing revenue faster at 14.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 57/100) and 10.2% revenue growth. FBIO offers better value entry with a 73.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Fortress Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?